Hepatocellular Carcinoma Associated Lipid Metabolism Reprogramming
- 1 July 2011
- journal article
- Published by Elsevier in Journal of Surgical Research
- Vol. 169 (1) , 51-56
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Unique Ligand Selectivity of the GPR92/LPA5 Lysophosphatidate Receptor Indicates Role in Human Platelet ActivationJournal of Biological Chemistry, 2009
- NF-κB inhibition in human hepatocellular carcinoma and its potential as adjunct to sorafenib based therapyCancer Letters, 2009
- Evidence for lysophosphatidic acid 1 receptor signaling in the early phase of neuropathic pain mechanisms in experiments using Ki‐16425, a lysophosphatidic acid 1 receptor antagonistJournal of Neurochemistry, 2009
- Anastellin, the Angiostatic Fibronectin Peptide, Is a Selective Inhibitor of Lysophospholipid SignalingMolecular Cancer Research, 2009
- S32826, A Nanomolar Inhibitor of Autotaxin: Discovery, Synthesis and Applications as a Pharmacological ToolThe Journal of Pharmacology and Experimental Therapeutics, 2008
- The Biology of Cancer: Metabolic Reprogramming Fuels Cell Growth and ProliferationCell Metabolism, 2008
- Carba Analogs of Cyclic Phosphatidic Acid Are Selective Inhibitors of Autotaxin and Cancer Cell Invasion and MetastasisJournal of Biological Chemistry, 2006
- Cytokine stimulation of aerobic glycolysis in hematopoietic cells exceeds proliferative demandThe FASEB Journal, 2004
- Cooperation and Competition in the Evolution of ATP-Producing PathwaysScience, 2001
- A RAPID METHOD OF TOTAL LIPID EXTRACTION AND PURIFICATIONCanadian Journal of Biochemistry and Physiology, 1959